Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men

2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations

(2011) Jacques Genest et al.   CANADIAN JOURNAL OF CARDIOLOGY

Atorvastatin increases expression of low-density lipoprotein receptor mRNA in human circulating mononuclear cells

(2009) Anothai Pocathikorn et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia

(2009) André J Tremblay et al.   JOURNAL OF LIPID RESEARCH

A new method for measurement of total plasma PCSK9: clinical applications

(2009) Geneviève Dubuc et al.   JOURNAL OF LIPID RESEARCH

PCSK9 as a therapeutic target of dyslipidemia

(2008) Nabil G Seidah   EXPERT OPINION ON THERAPEUTIC TARGETS

Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men

(2007) Ioanna Gouni-Berthold et al.   CLINICAL ENDOCRINOLOGY